Auditoría interna de resultados oncológicos en la cirugía del cáncer gástrico / Internal audit of oncological results in gastric cancer surgery

Introducción: No hay apenas información nacional sobre los resultados oncológicos de la cirugía del cáncer gástrico, por lo que se utilizan cifras foráneas, que pueden ser absolutamente distintas de las locales. El objetivo de nuestro trabajo es analizar estos resultados en los pacientes intervenidos en nuestro centro. Métodos: Se analizan los resultados de supervivencia de 134 pacientes intervenidos por cáncer gástrico con intención curativa desde 2004 hasta junio de 2016. Resultados: El 76,8% de los pacientes (103/134) tenían estadios clínicos avanzados (≥ii), se realizó laparoscopia de estadificación en el 67% de los mismos (69/103), linfadenectomía extensa (≥LD1+) en el 89,3% (92/103), y recibieron QT perioperatoria el 76,7% (79/103). La distribución final por estadios patológicos 0, i, ii, iii y iv fue del 8,2; 20,2; 26,1; 37,3 y 8,2%, respectivamente. La mediana de seguimiento fue de 87 meses. La mediana de SG fue de 68 meses y la SG a uno, 3 y 5 años fue del 81,2, 62 y 53,8%, respectivamente. La SG a 5 años según el estadio patológico fue del 100% para el estadio 0, del 88,4% para el estadio i, del 62,5% para el estadio ii, del 23,6% para el estadio iii y del 17% para el estadio iv. Conclusiones: Nuestras tasas de supervivencia se encuentran en los rangos altos de la literatura occidental. No se han podido comparar con resultados nacionales debido al déficit de información sobre resultados oncológicos en la cirugía del cáncer gástrico en nuestro entorno más cercano (AU)

Introduction: National information on the oncological results of gastric cancer surgery is scarce, so foreign figures are used, which may completely differ from local ones. The aim of our study is to analyse these results in the patients operated on in our centre. Methods: Survival results of 134 patients that underwent gastric cancer surgery with curative intent from 2004 to June 2016 were analysed. Results: A percentage of 76.8 of the patients (103/134) presented in advanced clinical stages (≥ii). Staging laparoscopy was performed in 67% of them (69/103), an extensive lymphadenectomy (≥LD1+) was carried out in 89.3% of patients (92/103), and 76.7% (79/103) received perioperative chemotherapy. The distribution by pathological stage 0, i, ii, iii and iv was 8.2, 20.2, 26.1, 37.3, and 8.2%, respectively. Median follow-up was 87 months. Median OS was 68 months and one-, 3- and 5-year OS were 81.2, 62, and 53.8%, respectively. The 5-year OS according to pathological staging was 100% for stage 0, 88.4% for stage i, 62.5% for stage ii, 23.6% for stage iii and 17% for stage iv. Conclusions: Our survival rates are in the high ranges of western literature. These results could not be compared with national ones due to the lack of information regarding oncological outcomes in gastric cancer surgery in our closest environment (AU)

Internal audit of oncological results in gastric cancer surgery.

INTRODUCTION: National information on the oncological results of gastric cancer surgery is scarce, so foreign figures are used, which may completely differ from local ones. The aim of our study is to analyse these results in the patients operated on in our centre. METHODS: Survival results of 134 patients that underwent gastric cancer surgery with curative intent from 2004 to June 2016 were analysed. RESULTS: A percentage of 76.8 of the patients (103/134) presented in advanced clinical stages (≥ii). Staging laparoscopy was performed in 67% of them (69/103), an extensive lymphadenectomy (≥LD1+) was carried out in 89.3% of patients (92/103), and 76.7% (79/103) received perioperative chemotherapy. The distribution by pathological stage 0, i, ii, iii and iv was 8.2, 20.2, 26.1, 37.3, and 8.2%, respectively. Median follow-up was 87 months. Median OS was 68 months and one-, 3- and 5-year OS were 81.2, 62, and 53.8%, respectively. The 5-year OS according to pathological staging was 100% for stage 0, 88.4% for stage i, 62.5% for stage ii, 23.6% for stage iii and 17% for stage iv. CONCLUSIONS: Our survival rates are in the high ranges of western literature. These results could not be compared with national ones due to the lack of information regarding oncological outcomes in gastric cancer surgery in our closest environment.

Internal audit of oncological results in gastric cancer surgery. / Auditoría interna de resultados oncológicos en la cirugía del cáncer gástrico.

INTRODUCTION: National information on the oncological results of gastric cancer surgery is scarce, so foreign figures are used, which may completely differ from local ones. The aim of our study is to analyse these results in the patients operated on in our centre. METHODS: Survival results of 134 patients that underwent gastric cancer surgery with curative intent from 2004 to June 2016 were analysed. RESULTS: A percentage of 76.8 of the patients (103/134) presented in advanced clinical stages (≥ii). Staging laparoscopy was performed in 67% of them (69/103), an extensive lymphadenectomy (≥LD1+) was carried out in 89.3% of patients (92/103), and 76.7% (79/103) received perioperative chemotherapy. The distribution by pathological stage 0, i, ii, iii and iv was 8.2, 20.2, 26.1, 37.3, and 8.2%, respectively. Median follow-up was 87 months. Median OS was 68 months and one-, 3- and 5-year OS were 81.2, 62, and 53.8%, respectively. The 5-year OS according to pathological staging was 100% for stage 0, 88.4% for stage i, 62.5% for stage ii, 23.6% for stage iii and 17% for stage iv. CONCLUSIONS: Our survival rates are in the high ranges of western literature. These results could not be compared with national ones due to the lack of information regarding oncological outcomes in gastric cancer surgery in our closest environment.

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Carcinomatosis: Multicenter Study of Spanish Group of Peritoneal Oncologic Surgery (GECOP).

BACKGROUND: Gastric cancer (GC) with peritoneal carcinomatosis (PC) is traditionally considered a terminal stage of the disease. The use of a multimodal treatment, including cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), can benefit these patients. Our goal was to evaluate the morbidity and survival outcomes of these patients. METHODS: This is a retrospective, multicenter study from a prospective national database of patients diagnosed with PC secondary to GC treated with CRS and HIPEC from June 2006 to October 2017. RESULTS: Eighty-eight patients from seven specialized Spanish institutions were treated with CRS and HIPEC, with median age of 53 years; 51% were women. Median Peritoneal Cancer Index (PCI) was 6, and complete cytoreduction was achieved in 80 patients (90.9%). HIPEC was administered in 85 cases with 4 different regimens (Cisplatin + Doxorubicin, Mitomycin-C + Cisplatin, Mitomycin-C and Oxaliplatin). Twenty-seven cases (31%) had severe morbidity (grade III-IV) and 3 patients died in the postoperative period (3.4%). Median follow-up was 32 months. Median overall survival (OS) was 21.2 months, with 1-year OS of 79.9% and 3-year OS of 30.9%. Median disease-free survival (DFS) was 11.6 months, with 1-year DFS of 46.1% and 3-year DFS of 21.7%. After multivariate analysis, the extent of peritoneal disease (PCI ≥ 7) was identified as the only independent factor that influenced OS (hazard ratio [HR] 2.37, 95% confidence interval [CI] 1.26-4.46, p = 0.007). CONCLUSIONS: The multimodal treatment, including CRS and HIPEC, for GC with PC can improve the survival results in selected patients (PCI < 7) and in referral centers.

Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with gastric cancer and peritoneal carcinomatosis.

BACKGROUND: Gastric Cancer (GC) with Peritoneal Carcinomatosis (PC) has long been regarded as a terminal disease. Over the past two decades, cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has changed the traditional concept of peritoneal metastases from being a systemic disease, to being considered a locoregional dissemination. PATIENTS AND METHODS: A prospective study was performed at a high-volume Carcinomatosis Center to evaluate survival, morbi-mortality and prognostic factors for survival in a cohort of patients with GC and PC treated with CRS + HIPEC between June 2006 and December 2016. RESULTS: Thirty-five patients were included in the study. Median follow-up was 54 months. Postoperative major complications (>grade IIIa) occurred in 25.7% of patients, including 2 deaths (mortality 5.7%). The median overall survival (OS) was 16 months and the 1-, 3- and 5-year OS rates were 70.8%, 21.3% and 21.3% %, respectively. The median OS for patients with PCI ≤6 was 19 months, in contrast to 12 months for the 19 patients with PCI >6. Three patients were included with only a positive cytology and their median OS was not reached. Perineural invasion was the only factor that had a negative influence in prognosis (HR 18.8) in multivariate analysis. CONCLUSION: Although GC with PC still has a poor prognosis, survival has improved in selected patients with CRS + HIPEC and perioperative systemic chemotherapy. Patients with isolated positive cytology or peritoneal carcinomatosis with PCI less than 6 had encouraging survival rates.

Conversion of an Open Salmon's Technique to a Laparoscopic Gastric Bypass.

BACKGROUND: There are a growing number of patients who require revisional bariatric surgery due to the failure of their primary procedures. The aim of this video is to present a laparoscopic revisional procedure for dysphagia and gastroesophageal reflux disease (GERD) after an uncommonly performed bariatric surgery, Salmon's technique, consisting of a vertical banded gastroplasty and a horizontal stomach stapling with a Roux-en-Y bypass. METHODS: A 42-year-old obese male, with a history of dyslipidemia and a current body mass index (BMI) of 33, presented with severe dysphagia to solids and frequent spitting 10 years after the primary bariatric surgery (Salmon's procedure) with a BMI of 43. Endoscopy revealed a hiatal hernia. The endoscope passed down without difficulty to the antrum-duodenum and to efferent loop of the small bowel, demonstrating the presence of a fistula in the horizontal stapling of the stomach. Helicobacter pylori was negative. Esophageal transit showed the contrast passing adequately through the esophagogastric junction. Esophageal manometry revealed a hypotensive lower esophageal sphincter (mean pressure of 8 mmHg) and an ineffective peristalsis (40% of waves with normal amplitude and duration). Esophageal pHmetry showed severe GERD with a DeMeester score of 88.5 and a pH less than four, 18.7% of the total time. The patient was on PPIs at the time of symptom evaluation, but stopped the treatment before the performance of the pH study. Laparoscopic conversion to a Roux-en-Y gastric bypass was successfully performed. An extensive adhesiolysis was needed. The esophageal hiatus was dissected and the stomach was partially descended to reduce the hiatal hernia. A subsequent hiatal closure was performed. The efferent loop of the small bowel was freed from the gastric pouch. The new gastric pouch was performed stapling superiorly to the gastric ring and medially to the vertical gastroplasty. The new gastrojejunal anastomosis was performed using a mechanical linear stapler, in an antecolic fashion, and checked for leaks using methylene blue dye. RESULTS: The procedure took 300 min and no intraoperative complications occurred. The patient had an uneventful postoperative course, with a hospital stay of 4 days. One month after the revisional surgery, the patient presented with a stenosis of the gastrojejunal anastomosis, which was successfully solved after two endoscopic dilations. A year and a half after revisional surgery, the patient is completely asymptomatic, has a BMI of 29, and dyslipidemia as the only comorbidity. CONCLUSIONS: Salmon's technique is an uncommon bariatric procedure. Revisional surgery might be needed in case of late complications, like dysphagia and reflux, as it was the case in our patient. In addition, a fistula in the previous horizontal partitioning of the stomach was present. Laparoscopic conversion from Salmon's technique to a gastric bypass was decided. This procedure was successful in solving patient's symptoms and resulted in an increased weight lost. Laparoscopic revisional surgery after an open Salmon's technique is a complex procedure with an increased risk of complications. Our patient developed an anastomotic stenosis 1 month after surgery, probably due to the use of the same gauge as in non-fibrotic tissues.

Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.

BACKGROUND: Peritoneal dissemination is the most common route of spread of epithelial ovarian cancer (EOC). Cytoreductive surgery (CRS) followed by platinum-based systemic chemotherapy is the current standard treatment in advanced stages, with suboptimal results. The aim of this study is to analyze the outcome of advanced EOC treated with CRS plus hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) combined with systemic chemotherapy. METHODS: We analyze a cohort of women treated with CRS plus HIPEC for peritoneal carcinomatosis secondary to EOC from May 2007 to December 2014. We included both patients with peritoneal disease at first diagnosis of EOC and peritoneal recurrences after initial treatment. RESULTS: We performed 61 CRS with HIPEC procedures, 31 cases as primary treatment (4 as upfront therapy and 27 after neoadjuvant chemotherapy) and 30 as secondary treatment (recurrences). Median Peritoneal Carcinomatosis Index (PCI) was 9; the cytoreduction was optimal in 92% of the procedures. Severe morbidity (Grade III-IV of Clavien-Dindo classification) was 29.5%, without mortality. Median follow-up was 23 months and median disease-free survival (DFS) was 14 months (14 in primary surgery group and 17 in recurrence group, P=0.51). Median overall survival (OS) was 57 months; in primary surgery group, OS was 96.8% at 1 year, and 55% at 5 years, and median OS was not reached; OS in recurrence group was 89.3% at 1 year and 47.1% at 5 years, and median OS was 57 months. CONCLUSIONS: CRS with HIPEC is a treatment option for EOC with good results in terms of morbidity and survival, in experienced centers.